Endostar is one of 89 small molecule programs targeting Lung Cancer. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
206 competitors in Lung Cancer
Keytruda
Opdivo
Beyfortus
Yervoy
Abraxane
Imjudo
Alunbrig
Alecensa
DATROWAY
Verzenio
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details